| | |
| Clinical data | |
|---|---|
| Other names | 4-Fluoro-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-fluorophenethylamine |
| Routes of administration | Oral [1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Onset of action | Unknown [1] |
| Duration of action | Unknown [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H14FNO2 |
| Molar mass | 199.225 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
2C-F, also known as 4-fluoro-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and 2C families. [1] [2] It is taken orally. [1]
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists the dose of 2C-F as greater than 250 mg orally and its duration as unknown. [1] At a dose of 250 mg, 2C-F produces slight and uncertain effects including possible modest closed-eye visuals and pleasant lethargy. [1]
Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-F. [1] [3]
2C-F may be found as a brownish freebase oil, or as a white crystalline hydrochloride salt.
The chemical synthesis of 2C-F has been described. [1]
Analogues of 2C-F include 2C-B, 2C-I, 2C-C, DOF, and 25F-NBOMe, among others. [1]
2C-F was first described in the literature by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). [1]
As of October 31, 2016, 2C-F is a controlled substance (Schedule III) in Canada. [4]
| Phenethylamines |
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphetamines |
| ||||||||||||||||
| Phentermines |
| ||||||||||||||||
| Cathinones |
| ||||||||||||||||
| Phenylisobutylamines (and further-extended) | |||||||||||||||||
| Catecholamines (and close relatives) |
| ||||||||||||||||
| Cyclized phenethylamines |
| ||||||||||||||||
| Related compounds |
| ||||||||||||||||